0 Responses Abattis News | Experion | Northern Vine

VANCOUVER, BC / ACCESSWIRE / October 17, 2016

Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), announces commencement of construction for the Experion secure, production facility.

Experion Biotechnologies Inc. is pleased to announce that it has begun the construction process and prepares to break ground for the six-month build-out for its 8,000 square foot, phase one facility. This first phase will provide the operational infrastructure needed to continue forward through the licensing process.

Experion, a Licensed Producer Applicant, is located one hour east of the heart of downtown Metro Vancouver. Sean MacNeil, of Experion’s Communications, says: “Our facility location allows for cost-effective transportation and logistical controls as well as being out of the way from the hustle and bustle of the central business district of the Vancouver, Burnaby and Richmond hubs. We are best positioned to take competitive advantage of our location, and serve as the primary provider of product and starting materials for the industry.”

Experion has taken the communication from the federal government very seriously; implementing its approved design and proprietary operating systems, while raising all necessary funds to complete construction. A fast-track program is now in place to complete the facility during Q1 of 2017.

Phase Two expansion plans will provide the ability to have a continuous self-supply of product and a fulfillment centre that will be will be second to none. Experion’s 10-acres has the capability to have a canopy of approximately 350,000 square feet with access to additional acreage that will allow for perpetual and secure production.

Rene David, CEO of Abattis Bioceuticals says: “The team at Experion have been preparing for this moment and are focussed on being industry leaders. We are very happy for Experion and wish them the best during this next stage of approvals. Experion has recently achieved their ‘Pending Readiness Status’. We are fortunate to be associated with Experion and will remain supportive through their approval process.” The combination of Experion and Northern Vine Canada Inc., which have a mutual 25% ownership, allows for large cost savings, especially under the new ACMPR regulations. Not only will there be the access to testing for dried or oil-based medical marihuana, there is also the testing of starting materials as part of the potential Experion offering. Having access to an analytical testing lab also allows for the ease of future formulations and the need for best extraction technology.

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company also is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

About Northern Vine Canada Inc.

Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.

ON BEHALF OF THE BOARD

Rene David
Rene David, CFO, Acting CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

Leave a Reply

Your email address will not be published. Required fields are marked *